RIPK1

Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Wednesday, October 6, 2021
Goal, Neurodegeneration, Review, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, AD, Communication, RIPK1, Safety, SEC, Neuron, Food, Biomarker, PTV, Pathology, Traffic barrier, Central nervous system, Adult, Prisoner transport vehicle, MS, Frontotemporal dementia, VWM, CNS, Mouse, Clinical trial, Therapy, Inflammation, White matter, NASDAQ, U.S. Securities and Exchange Commission, FDA, Fast Track, Blood, EIF2B, ISR, Marketing, Human, Lists of diseases, Risk, Brain, Forward-looking statement, FTD, Multiple sclerosis, GLOBE, Pharmacokinetics, PK, Security (finance), Amyotrophic lateral sclerosis, Patient, Preclinical development, COVID-19, PD, ALS, Sanofi, BBB, Pharmaceutical industry, Communications satellite, Medical device

DNL343 and SAR443820 are designed to modulate distinct biological pathways implicated in ALS, including the integrated stress response and inflammation, respectively.

Key Points: 
  • DNL343 and SAR443820 are designed to modulate distinct biological pathways implicated in ALS, including the integrated stress response and inflammation, respectively.
  • Denali presented positive results from a Phase 1 study in healthy volunteers (n=95) in which safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses of DNL343 were evaluated.
  • Denali and Sanofi entered into a broad collaboration in October 2018 for the global development and commercialization of RIPK1 inhibitors.
  • The forward-looking statements in this press release are based on information available to Denali as of the date hereof.

Denali Therapeutics Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting

Retrieved on: 
Wednesday, September 29, 2021
CNS, Safety, Neurodegeneration, Pharmacokinetics, PTV, EIF2B, Integrated stress response, PHASE 2, Security (finance), Private Securities Litigation Reform Act, NASDAQ, U.S. Securities and Exchange Commission, Amyotrophic lateral sclerosis, Pathology, Traffic barrier, Biomarker, AD, Prisoner transport vehicle, GLOBE, MS, Efficacy, Risk, COVID-19, Placebo-controlled study, ClinicalTrials.gov, ALS, RIPK1, Forward-looking statement, Randomness, Sanofi, FTD, Frontotemporal dementia, BBB, Multiple sclerosis, SEC, Neuron, Pharmaceutical industry

EIF2B is an intracellular protein complex that regulates protein synthesis and is required for neuronal health and function.

Key Points: 
  • EIF2B is an intracellular protein complex that regulates protein synthesis and is required for neuronal health and function.
  • DNL343 is designed to activate EIF2B and thereby restore protein synthesis, disperse TDP-43 aggregates, and improve neuronal survival.
  • Denali and Sanofi entered into a broad collaboration in October 2018 for the global development and commercialization of RIPK1 inhibitors.
  • During the webinar, Denali will review the NEALS presentations related to its investigational small molecule therapeutics DNL343 and SAR443820.

Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in Cutaneous Lupus Erythematosus (CLE) Patients

Retrieved on: 
Monday, June 28, 2021
Companies, CAC 40, Sanofi, RIPK1, Health care, Insulin glargine/lixisenatide

Denali and Sanofi entered into a broad collaboration inOctober 2018for the global development and commercialization of RIPK1 inhibitors.

Key Points: 
  • Denali and Sanofi entered into a broad collaboration inOctober 2018for the global development and commercialization of RIPK1 inhibitors.
  • Under the agreement, Denali will receive a milestone payment of $15 million related to the Phase 2 study with DNL758 from Sanofi.
  • Sanofi is responsible for the development and commercialization of DNL758 and covers all costs related to DNL758.
  • Further information on the Phase 2 clinical study of DNL758for CLE (study number NCT04781816) can be accessed on theClinicalTrials.govwebsite or by clicking here .

Rigel Announces Closing of Strategic Collaboration with Lilly

Retrieved on: 
Wednesday, April 7, 2021
RIPK1, Protein kinases, Protein kinase

Rigel and Lilly entered a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases.

Key Points: 
  • Rigel and Lilly entered a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases.
  • Pursuant to the collaboration, Lilly will also lead all clinical development of penetrating RIPK1 inhibitors in central nervous system (CNS) diseases.
  • The agreement is effective as of March 27, 2021and Rigel has received the$125 million upfront cash payment due under the terms of the agreement from Lilly.
  • Additional details about the collaboration can be found in Rigel's Form 8-K filed with the Securities and Exchange Commission on February 18, 2021.

Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases

Retrieved on: 
Thursday, February 18, 2021
RIPK1, Eli Lilly and Company, Rigel, Eli Lilly, Life sciences, Economy of the United States, Companies

Pursuant to the collaboration, Lilly will also lead all clinical development of brain penetrating RIPK1 inhibitors in central nervous system (CNS) diseases.

Key Points: 
  • Pursuant to the collaboration, Lilly will also lead all clinical development of brain penetrating RIPK1 inhibitors in central nervous system (CNS) diseases.
  • Rigel's lead RIPK1 inhibitor, R552, has completed Phase 1 clinical trials and will begin Phase 2 clinical trials in 2021 as part of the collaboration.
  • Under the terms of the agreement, Lilly will pay an upfront cash payment to Rigel of $125 million.
  • Rigel Investor Contact - (650) 624-1232; [email protected]
    Rigel Media Contact (508) 314-3157; [email protected]
    View original content to download multimedia: http://www.prnewswire.com/news-releases/lilly-and-rigel-enter-strategic-...
    SOURCE Eli Lilly and Company; Rigel Pharmaceuticals

Denali Therapeutics Announces Phase 1b Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in COVID-19 Patients

Retrieved on: 
Wednesday, July 29, 2020
Companies, CAC 40, Sanofi, RIPK1, Articles, Health, Coronavirus disease

Our partner Sanofiis expanding its clinical investigation of DNL758 into patients with severe COVID-19.

Key Points: 
  • Our partner Sanofiis expanding its clinical investigation of DNL758 into patients with severe COVID-19.
  • We are proud to stand with Sanofi in this effort, with the aim to contribute solutions in the fight against this terrible pandemic.
  • Denali and Sanofi entered a broad partnership in October 2018 for the global development and commercialization of RIPK1 inhibitors.
  • Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases.

Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi

Retrieved on: 
Tuesday, June 9, 2020
RIPK1, Tumor necrosis factor alpha, RIPK3, RIP kinase

RIPK1, receptor-interacting serine/threonine-protein kinase 1, is a critical signaling protein in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body.

Key Points: 
  • RIPK1, receptor-interacting serine/threonine-protein kinase 1, is a critical signaling protein in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body.
  • Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the BBB for neurodegenerative diseases.
  • The forward-looking statements in this press release are based on information available to Denali as of the date hereof.
  • Denali disclaims any obligation to update any forward-looking statements, except as required by law.

Denali Therapeutics Announces That Its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study

Retrieved on: 
Monday, August 5, 2019
RIPK1, Companies, Sanofi, Economy of France, Life sciences

Sanofi has commenced dosing of DNL758 in a Phase 1 healthy volunteer study.

Key Points: 
  • Sanofi has commenced dosing of DNL758 in a Phase 1 healthy volunteer study.
  • DNL758 is an investigational small molecule RIPK1 inhibitor that does not cross the blood-brain barrier, and is intended for peripheral diseases.
  • This triggers a milestone payment of $10 million to Denali according to the Sanofi Collaboration Agreement for RIPK1 inhibitors.
  • Denali and Sanofi are developing several molecules targeting RIPK1 inhibition, including DNL747 in neurological indications and DNL758 in several non-neurological indications.